Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more
Biomm S.A (BIOM3) - Net Assets
Latest net assets as of September 2025: R$284.10 Million BRL
Based on the latest financial reports, Biomm S.A (BIOM3) has net assets worth R$284.10 Million BRL as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$485.03 Million) and total liabilities (R$200.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$284.10 Million |
| % of Total Assets | 58.57% |
| Annual Growth Rate | 19.8% |
| 5-Year Change | 37.24% |
| 10-Year Change | 128.25% |
| Growth Volatility | 65.78 |
Biomm S.A - Net Assets Trend (2004–2024)
This chart illustrates how Biomm S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biomm S.A (2004–2024)
The table below shows the annual net assets of Biomm S.A from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$262.78 Million | +113.75% |
| 2023-12-31 | R$122.94 Million | -22.73% |
| 2022-12-31 | R$159.11 Million | +42.59% |
| 2021-12-31 | R$111.59 Million | -41.72% |
| 2020-12-31 | R$191.48 Million | +24.70% |
| 2019-12-31 | R$153.56 Million | +44.74% |
| 2018-12-31 | R$106.09 Million | +78.90% |
| 2017-12-31 | R$59.30 Million | -10.05% |
| 2016-12-31 | R$65.93 Million | -42.73% |
| 2015-12-31 | R$115.13 Million | +7.49% |
| 2014-12-31 | R$107.10 Million | -1.68% |
| 2013-12-31 | R$108.94 Million | +595.28% |
| 2012-12-31 | R$-22.00 Million | -151.14% |
| 2011-12-31 | R$-8.76 Million | -115.66% |
| 2010-12-31 | R$-4.06 Million | -26973.33% |
| 2009-12-31 | R$-15.00K | +99.88% |
| 2008-12-31 | R$-12.22 Million | -448.05% |
| 2007-12-31 | R$-2.23 Million | -172.16% |
| 2006-12-31 | R$3.09 Million | +0.19% |
| 2005-12-31 | R$3.08 Million | -56.50% |
| 2004-12-31 | R$7.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomm S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65364200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | R$900.00 Million | 342.49% |
| Other Comprehensive Income | R$677.00K | 0.26% |
| Other Components | R$15.75 Million | 5.99% |
| Total Equity | R$262.78 Million | 100.00% |
Biomm S.A Competitors by Market Cap
The table below lists competitors of Biomm S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ashiana Housing Limited
NSE:ASHIANA
|
$100.86 Million |
|
Viking Tech
TWO:3624
|
$100.87 Million |
|
ThinTech Materials Technology Co Ltd
TWO:3663
|
$100.90 Million |
|
ABOV Semiconductor Co. Ltd
KQ:102120
|
$100.94 Million |
|
Huayang Intelligent Co Ltd
SHE:301502
|
$100.82 Million |
|
BEEKS FIN CLD LS-00125
F:1BZ
|
$100.73 Million |
|
Paysign Inc
NASDAQ:PAYS
|
$100.71 Million |
|
Sula Vineyards Limited
NSE:SULA
|
$100.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomm S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 122,940,000 to 262,784,000, a change of 139,844,000 (113.7%).
- Net loss of 77,238,000 reduced equity.
- Share repurchases of 217,012,000 reduced equity.
- New share issuances of 217,012,000 increased equity.
- Other comprehensive income increased equity by 70,000.
- Other factors increased equity by 217,012,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$-77.24 Million | -29.39% |
| Share Repurchases | R$217.01 Million | -82.58% |
| Share Issuances | R$217.01 Million | +82.58% |
| Other Comprehensive Income | R$70.00K | +0.03% |
| Other Changes | R$217.01 Million | +82.58% |
| Total Change | R$- | 113.75% |
Book Value vs Market Value Analysis
This analysis compares Biomm S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.48x to 3.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | R$0.32 | R$6.95 | x |
| 2006-12-31 | R$0.32 | R$6.95 | x |
| 2007-12-31 | R$-0.23 | R$6.95 | x |
| 2008-12-31 | R$-1.35 | R$6.95 | x |
| 2009-12-31 | R$0.00 | R$6.95 | x |
| 2010-12-31 | R$-0.23 | R$6.95 | x |
| 2011-12-31 | R$-0.49 | R$6.95 | x |
| 2012-12-31 | R$-1.21 | R$6.95 | x |
| 2013-12-31 | R$5.81 | R$6.95 | x |
| 2014-12-31 | R$3.32 | R$6.95 | x |
| 2015-12-31 | R$3.56 | R$6.95 | x |
| 2016-12-31 | R$2.05 | R$6.95 | x |
| 2017-12-31 | R$1.71 | R$6.95 | x |
| 2018-12-31 | R$2.41 | R$6.95 | x |
| 2019-12-31 | R$3.05 | R$6.95 | x |
| 2020-12-31 | R$3.03 | R$6.95 | x |
| 2021-12-31 | R$1.59 | R$6.95 | x |
| 2022-12-31 | R$2.16 | R$6.95 | x |
| 2023-12-31 | R$1.48 | R$6.95 | x |
| 2024-12-31 | R$2.15 | R$6.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomm S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.05%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.77x
- Recent ROE (-29.39%) is above the historical average (-30.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -129.91% | -142.58% | 0.18x | 5.10x | R$-4.31 Million |
| 2006 | 0.19% | 0.09% | 0.60x | 3.61x | R$-302.90K |
| 2007 | 0.00% | -266.57% | 0.21x | 0.00x | R$-5.10 Million |
| 2008 | 0.00% | -245.74% | 0.25x | 0.00x | R$-6.19 Million |
| 2009 | 0.00% | -941.94% | 0.06x | 0.00x | R$-5.73 Million |
| 2010 | 0.00% | -487.23% | 0.18x | 0.00x | R$-3.87 Million |
| 2011 | 0.00% | -2023.81% | 0.02x | 0.00x | R$-3.80 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | R$-11.94 Million |
| 2013 | -9.23% | 0.00% | 0.00x | 1.27x | R$-20.95 Million |
| 2014 | -11.87% | 0.00% | 0.00x | 1.68x | R$-23.42 Million |
| 2015 | 7.19% | 0.00% | 0.00x | 1.99x | R$-3.23 Million |
| 2016 | -69.18% | 0.00% | 0.00x | 3.60x | R$-52.20 Million |
| 2017 | -64.30% | -37017.48% | 0.00x | 4.42x | R$-44.06 Million |
| 2018 | -40.12% | -2717.88% | 0.01x | 2.88x | R$-53.17 Million |
| 2019 | -36.35% | -624.02% | 0.02x | 2.53x | R$-71.17 Million |
| 2020 | -36.96% | -120.62% | 0.13x | 2.27x | R$-89.91 Million |
| 2021 | -71.93% | -74.95% | 0.29x | 3.31x | R$-91.42 Million |
| 2022 | -58.17% | -88.19% | 0.26x | 2.55x | R$-108.47 Million |
| 2023 | -66.00% | -68.65% | 0.34x | 2.80x | R$-93.44 Million |
| 2024 | -29.39% | -54.05% | 0.31x | 1.77x | R$-103.52 Million |
Industry Comparison
This section compares Biomm S.A's net assets metrics with peer companies in the Biotechnology industry.
No peer company data available for comparison.